// App-Quantinova.ai

2045 : Relationship of venetoclax dose and exposure to response in relapsed or refractory chronic lymphocytic leukemia and non-Hodgkin's lymphoma subjects

Researchers

Presenter

  • Kevin J. Freise

Principal Investigators

  • Aksana K. Jones

  • Doerthe Eckert

  • Sven Mensing

  • Shekman Wong

  • Rod Humerickhouse

  • Walid Awni

  • Ahmed H. Salem

Medical Centers

  • AbbVie, Inc., North Chicago, IL

  • Abbvie, Ludwigshafen, Germany

  • AbbVie, Redwood City, CA

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Hematological malignancies

  • Non-Hodgkin's Lymphoma

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Non‐Hodgkin Lymphoma

  • Neutropenia

  • Lymphomas

  • Solid malignancies

Biomarkers

  • B-cell lymphoma 2

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved